When standard leukaemia treatments failed, 13-year-old Alyssa Tapley was told she had only weeks left. Then she was offered an experimental procedure that would ultimately save her life, making her the first person whose life was saved by CRISPR base editing.
Base editing is a more precise form of CRISPR that changes single letters of DNA without cutting the double helix. This technique was used to modify immune cells to attack Tapley's cancer, a strategy that had never before succeeded in a human patient.
Tapley's case was reported by New Scientist, which noted that the procedure was experimental and not yet widely available. The success marks a significant milestone for the field, though the details of the treatment protocol, including exact dosing and long-term outcomes, have not been fully disclosed.
While this single case offers hope, it does not prove the therapy will work for all patients. More trials are needed to establish safety and efficacy across different cancer types and stages of disease.
Some ethicists caution that such early successes can lead to premature hype, noting that rigorous phase III trials remain the gold standard before clinical adoption.